Creating a serum bank to find early markers for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a serum library from patients with adenocarcinoma to evaluate various serum biomarkers, including adiponectin, for the early diagnosis of pancreatic cancer. The study will collect blood samples from participants at different stages of the disease, focusing on those who are starting treatment. By comparing these samples to a control group, researchers hope to identify potential blood markers that could facilitate earlier detection of pancreatic cancer, which is often diagnosed at advanced stages. The ultimate goal is to improve diagnostic methods and patient outcomes.

Why it matters

Who can join: the full rules

ADENOCARCINOMA GROUP

Inclusion Criteria:

* Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis.
* At the start of treatment (before surgery / 1st course of chemotherapy)
* Age ≥ 18 years
* Patient affiliated or entitled to a social security system

Exclusion Criteria:

* Patient refusal
* Acute renal failure
* Child-Pugh B or C cirrhosis
* Patient under guardianship or curators
* Other synchronous cancer or history of cancer \<5 years
* Language barrier

CONTROL GROUP

Inclusion Criteria:

* Age ≥ 40 years
* Patient affiliated or entitled to a social security system
* Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease

Exclusion Criteria:

* Patient refusal
* Acute renal failure
* Child-Pugh B or C cirrhosis
* Patient under guardianship or curators
* Other synchronous cancer or history of cancer \<5 years

Where it's running

• CHU Saint-Etienne
  Saint-Etienne, France Recruiting
• Institut Cancérologique Lucien Newirth (ICLN)
  Saint-Priest-en-Jarez, France Recruiting

Study contacts

• Principal investigator: Nicolas WILLIET, MD — Centre Hospitalier Universitaire de Saint Etienne
• Study coordinator: Nicolas WILLIET, MD
• Email: nicolas.williet@chu-st-etienne.fr
• Phone: (0)477829029

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

• LM-302 with tislelizumab plus chemotherapy for stomach and gastroesophageal junction cancer

  This phase 3 study tests whether LM-302 added to tislelizumab is better or safer than tislelizumab with chemotherapy in patients with newly diagnosed, unresectable or metastatic stomach/GEJ adenocarcinoma that express CLDN18.2.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 105 other locations · NCT07385703

• Relacorilant with nab-paclitaxel and gemcitabine for metastatic pancreatic adenocarcinoma

  This trial tests whether adding relacorilant to standard chemotherapy (nab-paclitaxel plus gemcitabine) helps people with previously untreated metastatic pancreatic adenocarcinoma.

  Recruiting at 19 sites Phase 2 Corcept Therapeutics · Scottsdale, Arizona and 19 other locations · NCT07259317

• Long-term clinical and tissue data collection for people with thoracic cancers

  This project will collect medical records, imaging, quality-of-life information, and tissue/blood samples over time from adults with thoracic cancers to try to find factors that predict outcomes.

  Recruiting at 11 sites Dutch Society of Physicians for Pulmonology and Tuberculosis · Ede, Gelderland and 22 other locations · NCT06996249

• Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer

  This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06794073

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.